Table 6.

Multivariable association of severity of AKI and change (fold increase) in level of urine protein-to-creatinine ratio using an AKI versus matched non-AKI episode modeling approach (i.e., comparing only a single pair of pre- and post-study visits urine protein-to-creatinine ratios) overall and analyses that exclude receipt of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or systolic BP level

Comparisons	Full Model		Model Excluding Receipt of ACE-I/ARB		Model Excluding Systolic BP Level
	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value	Relative Risk (95% CI)	P Value
AKI stage 1 between study visits (versus no AKI)	1.03 (0.92 to 1.16)	0.59	1.03 (0.92 to 1.16)	0.57	1.00 (0.88 to 1.12)	0.95
AKI stage 2 between study visits (versus no AKI)	1.07 (0.91 to 1.26)	0.43	1.07 (0.90 to 1.26)	0.44	1.06 (0.90 to 1.26)	0.48
AKI stage 3 between study visits (versus no AKI)	1.32 (1.12 to 1.55)	<0.001	1.32 (1.13 to 1.56)	<0.001	1.29 (1.09 to 1.53)	<0.01

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 95% CI, 95% confidence interval.